0001209191-21-048385.txt : 20210727 0001209191-21-048385.hdr.sgml : 20210727 20210727205718 ACCESSION NUMBER: 0001209191-21-048385 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210722 FILED AS OF DATE: 20210727 DATE AS OF CHANGE: 20210727 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: DENG FENG CENTRAL INDEX KEY: 0001165399 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40632 FILM NUMBER: 211119508 MAIL ADDRESS: STREET 1: SUITE 1701, 17/F HUTCHISON HOUSE STREET 2: 10 HARCOURT ROAD, CENTRAL CITY: HONG KONG STATE: K3 ZIP: 00000 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Cytek Biosciences, Inc. CENTRAL INDEX KEY: 0001831915 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] IRS NUMBER: 472547526 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 46107 LANDING PARKWAY CITY: FREMONT STATE: CA ZIP: 94538 BUSINESS PHONE: (877) 922-9835 MAIL ADDRESS: STREET 1: 46107 LANDING PARKWAY CITY: FREMONT STATE: CA ZIP: 94538 FORMER COMPANY: FORMER CONFORMED NAME: Cytek BioSciences, Inc. DATE OF NAME CHANGE: 20201110 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-07-22 0 0001831915 Cytek Biosciences, Inc. CTKB 0001165399 DENG FENG 2855 SAND HILL ROAD MENLO PARK CA 94025 1 0 0 0 Common Stock 2021-07-22 4 C 0 147933 A 147933 I See footnote Common Stock 2021-07-22 4 C 0 4168777 A 4168777 I See footnote Common Stock 2021-07-22 4 C 0 443800 A 443800 I See footnote Series A Preferred Stock 2021-07-22 4 C 0 147933 0.00 D Common Stock 147933 0 I See footnote Series C Preferred Stock 2021-07-22 4 C 0 4168777 0.00 D Common Stock 4168777 0 I See footnote Series D Preferred Stock 2021-07-22 4 C 0 443800 0.00 D Common Stock 443800 0 I See footnote Each share of Preferred Stock automatically converted on a one-for-one basis into Common Stock upon the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration. The shares of Preferred Stock have no expiration date. Shares held directly by Northern Light Venture Capital V, Ltd. ("NLVC V"). Fund V serves as the nominee for each of Northern Light Venture Fund V, L.P., Northern Light Strategic Fund V, L.P. and Northern Light Partners Fund V, L.P (together, the "NLVC V Funds"). Northern Light Partners V, L.P., a Cayman Islands exempted limited liability partnership, is the general partner of the NLVC V Funds. NLVC V is the general partner of Northern Light Partners V, L.P. Feng Deng is the controlling shareholder of NLVC V and may be deemed to have voting and dispositive power with respect to the shares held by NLVC V. /s/ Valerie Barnett, Attorney-in-Fact for Feng Deng 2021-07-27